EA201591762A1 - Человеческие антитела к grem1 - Google Patents
Человеческие антитела к grem1Info
- Publication number
- EA201591762A1 EA201591762A1 EA201591762A EA201591762A EA201591762A1 EA 201591762 A1 EA201591762 A1 EA 201591762A1 EA 201591762 A EA201591762 A EA 201591762A EA 201591762 A EA201591762 A EA 201591762A EA 201591762 A1 EA201591762 A1 EA 201591762A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- grem1
- antibodies
- present
- human antibodies
- bind
- Prior art date
Links
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 title abstract 2
- 102100038367 Gremlin-1 Human genes 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 102000046318 human GREM1 Human genes 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782874P | 2013-03-14 | 2013-03-14 | |
| US201361883218P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/021471 WO2014159010A1 (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591762A1 true EA201591762A1 (ru) | 2015-12-30 |
Family
ID=50390267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591762A EA201591762A1 (ru) | 2013-03-14 | 2014-03-07 | Человеческие антитела к grem1 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10377817B2 (enExample) |
| EP (1) | EP2970448B1 (enExample) |
| JP (2) | JP6581075B2 (enExample) |
| KR (1) | KR20150129718A (enExample) |
| CN (1) | CN105189548A (enExample) |
| AU (1) | AU2014241442B2 (enExample) |
| BR (1) | BR112015021979A2 (enExample) |
| CA (1) | CA2904644C (enExample) |
| CL (1) | CL2015002603A1 (enExample) |
| EA (1) | EA201591762A1 (enExample) |
| ES (1) | ES2898620T3 (enExample) |
| HK (1) | HK1220469A1 (enExample) |
| IL (1) | IL240769A0 (enExample) |
| MX (1) | MX369574B (enExample) |
| PH (1) | PH12015501865A1 (enExample) |
| SG (2) | SG10201707518YA (enExample) |
| WO (1) | WO2014159010A1 (enExample) |
| ZA (1) | ZA201506113B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2790992C2 (ru) * | 2018-02-15 | 2023-03-01 | Юсб Биофарма Срл | Ингибитор гремлина-1 для лечения перелома кости или дефекта кости |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
| AU2017252527A1 (en) | 2016-04-18 | 2018-11-08 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| CN106399316B (zh) * | 2016-08-26 | 2019-03-01 | 西安交通大学第一附属医院 | 用于识别Gremlin-1的核酸适配子及其应用 |
| EP3504238A1 (en) * | 2016-08-29 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| WO2018112334A1 (en) | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| CA3055305A1 (en) | 2017-03-22 | 2018-09-27 | Bluefin Biomedicine, Inc. | Anti-tmeff1 antibodies and antibody drug conjugates |
| WO2018175924A1 (en) * | 2017-03-24 | 2018-09-27 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| GB201802486D0 (en) * | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| JP7565219B2 (ja) | 2018-06-18 | 2024-10-10 | ユーシービー バイオファルマ エスアールエル | がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| EP4061852A4 (en) * | 2019-11-21 | 2024-03-13 | Unity Biotechnology | ANTIBODIES AGAINST TIE-2 AND METHODS OF USE |
| EP4232475A1 (en) * | 2020-10-20 | 2023-08-30 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
| WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| US20240294622A1 (en) * | 2021-01-18 | 2024-09-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| EP4511395A1 (en) * | 2022-04-20 | 2025-02-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| TW202409078A (zh) * | 2022-07-18 | 2024-03-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 穩定之包含抗gremlin1抗體的藥物製劑 |
| CN115786495A (zh) * | 2022-10-24 | 2023-03-14 | 杭州市第七人民医院 | 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途 |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| AU6267098A (en) | 1997-02-05 | 1998-08-25 | Regents Of The University Of California, The | Morphogenic proteins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| RU2336902C2 (ru) | 2001-10-31 | 2008-10-27 | Алькон, Инк. | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
| EP1777519A1 (en) | 2001-10-31 | 2007-04-25 | Alcon, Inc. | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| JP2008531525A (ja) | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007124486A2 (en) | 2006-04-21 | 2007-11-01 | Childrens Hospital Los Angeles | Bmp4 inhibitors |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| JP5410434B2 (ja) | 2007-09-28 | 2014-02-05 | バインド セラピューティックス インコーポレイテッド | ナノ粒子を用いた癌細胞の標的化 |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
-
2014
- 2014-03-07 MX MX2015011616A patent/MX369574B/es active IP Right Grant
- 2014-03-07 JP JP2016500767A patent/JP6581075B2/ja active Active
- 2014-03-07 ES ES14713709T patent/ES2898620T3/es active Active
- 2014-03-07 HK HK16108451.7A patent/HK1220469A1/zh unknown
- 2014-03-07 BR BR112015021979A patent/BR112015021979A2/pt not_active Application Discontinuation
- 2014-03-07 WO PCT/US2014/021471 patent/WO2014159010A1/en not_active Ceased
- 2014-03-07 SG SG10201707518YA patent/SG10201707518YA/en unknown
- 2014-03-07 EP EP14713709.5A patent/EP2970448B1/en active Active
- 2014-03-07 US US14/775,637 patent/US10377817B2/en active Active
- 2014-03-07 EA EA201591762A patent/EA201591762A1/ru unknown
- 2014-03-07 CA CA2904644A patent/CA2904644C/en active Active
- 2014-03-07 SG SG11201506459PA patent/SG11201506459PA/en unknown
- 2014-03-07 CN CN201480014151.0A patent/CN105189548A/zh active Pending
- 2014-03-07 KR KR1020157024673A patent/KR20150129718A/ko not_active Withdrawn
- 2014-03-07 AU AU2014241442A patent/AU2014241442B2/en active Active
-
2015
- 2015-08-21 ZA ZA2015/06113A patent/ZA201506113B/en unknown
- 2015-08-23 IL IL240769A patent/IL240769A0/en unknown
- 2015-08-25 PH PH12015501865A patent/PH12015501865A1/en unknown
- 2015-09-11 CL CL2015002603A patent/CL2015002603A1/es unknown
-
2019
- 2019-05-08 JP JP2019087970A patent/JP2019151654A/ja active Pending
- 2019-06-27 US US16/454,663 patent/US11634480B2/en active Active
-
2023
- 2023-03-06 US US18/117,883 patent/US20230192831A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2790992C2 (ru) * | 2018-02-15 | 2023-03-01 | Юсб Биофарма Срл | Ингибитор гремлина-1 для лечения перелома кости или дефекта кости |
| RU2853818C1 (ru) * | 2021-03-11 | 2025-12-26 | Шанхай Цзяо Тун Юниверсити | Способ лечения заболеваний с применением антагонистов GREMLIN1 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105189548A (zh) | 2015-12-23 |
| BR112015021979A2 (pt) | 2017-08-29 |
| SG10201707518YA (en) | 2017-10-30 |
| SG11201506459PA (en) | 2015-09-29 |
| CA2904644A1 (en) | 2014-10-02 |
| IL240769A0 (en) | 2015-10-29 |
| US10377817B2 (en) | 2019-08-13 |
| JP6581075B2 (ja) | 2019-09-25 |
| EP2970448A1 (en) | 2016-01-20 |
| HK1220469A1 (zh) | 2017-05-05 |
| US20160024195A1 (en) | 2016-01-28 |
| US20230192831A1 (en) | 2023-06-22 |
| JP2019151654A (ja) | 2019-09-12 |
| MX2015011616A (es) | 2015-12-17 |
| CL2015002603A1 (es) | 2016-03-04 |
| ZA201506113B (en) | 2016-07-27 |
| CA2904644C (en) | 2022-09-20 |
| PH12015501865A1 (en) | 2015-12-07 |
| MX369574B (es) | 2019-11-13 |
| WO2014159010A1 (en) | 2014-10-02 |
| EP2970448B1 (en) | 2021-11-03 |
| KR20150129718A (ko) | 2015-11-20 |
| AU2014241442B2 (en) | 2018-11-15 |
| US11634480B2 (en) | 2023-04-25 |
| ES2898620T3 (es) | 2022-03-08 |
| US20200157194A1 (en) | 2020-05-21 |
| AU2014241442A1 (en) | 2015-10-15 |
| JP2016519650A (ja) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591762A1 (ru) | Человеческие антитела к grem1 | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| SA519402159B1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| EA201890754A1 (ru) | Соединения и способы их применения | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| MX375032B (es) | Proteínas de unión y métodos para utilizarlas. | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201590997A1 (ru) | Соединения и способы их применения | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| EA201491452A1 (ru) | Антитела к asic1 и их применение | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EA201591514A1 (ru) | Антитела к пан-хемокинам подсемейства elrcxc | |
| PH12015501360A1 (en) | Bmp-6 antibodies | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها |